Hypotrichosis Of Eyelashes - FDA Advisory Committee Unanimously Recommends Approval Of LATISSE™ (Bimatoprost Solution 0.03%) Allergan, Inc. (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic
Drugs Advisory Committee (DODAC) voted unanimously (9-0) to recommend that the FDA approve LATISSE™ (bimatoprost solution 0.03%) as a treatment for hypotrichosis (or reduced amount of hair) of the eyelashes.
Source: www.medicalnewstoday.comThe Key To Managing HIV Could Lie In Extraordinary Immune Cells People who manage to control HIV on their own are providing scientists with valuable information about how the immune system eliminates virus-infected cells.
Source: www.medicalnewstoday.comGrowing Focus On PI3-Kinase Pathway In Cancer Research Reported In GEN Researchers are taking a closer look at the phosphoinositide 3-kinase (PI3-kinase) pathway as studies continue to demonstrate that inhibiting this biological route suppresses tumor growth, reports Genetic Engineering & Biotechnology News (GEN). The pathway is involved in angiogenesis, cell growth, differentiation, and survival.
Source: www.medicalnewstoday.comOre Pharmaceuticals Announces Completion Of Multiple Ascending Dose GL1001 Clinical Phase 1 Trial Ore Pharmaceuticals Inc. (NASDAQ: ORXE) today announced that it has completed dosing volunteer subjects in its multiple ascending dose clinical study of the Company's lead drug candidate, GL1001. The study, initiated in September, was a blinded, placebo-controlled study in 32
healthy volunteers which studied multiple ascending doses up through the highest planned dose of 1800mg.
Source: www.medicalnewstoday.comNike Foundation Calls On Global HIV-Prevention Initiatives To Focus On Girls Against the backdrop of World AIDS Week, the Nike Foundation has launched a global effort with government partners to put adolescent girls in developing countries at the center of HIV-prevention strategies. Every day, 6,000 young people ages 15 to 24 become infected with HIV. Two-thirds of these new cases are girls.
Source: www.medicalnewstoday.comProducing Functional, Oxygen-carrying Red Blood Cells From Mature Human Embryonic Stem Cells Advanced Cell Technology, Inc. ("ACT") (OTC: ACTC), announced today that their study investigating the feasibility of producing functional, oxygen-carrying red blood cells (RBCs) from mature human embryonic stem cells (hESCs) has been formally published in the print version of the prestigious medical journal Blood - the leading publication in the field of hematology.
Source: www.medicalnewstoday.comTesetaxel, Leading Oral Taxane In Clinical Development, Receives FDA Designation As An Orphan Drug For Treatment Of Patients With Advanced Melanoma Genta Incorporated (OTCBB: GNTA) announced today that the Company has received notice from the U.S. Food and Drug Administration (FDA) that tesetaxel, the Company's oral taxane in clinical development, has been granted designation as an "Orphan Drug" for treatment of patients with advanced melanoma.
Source: www.medicalnewstoday.com
# posted by Network @ 2:00 PM
